Tag Archives: m d anderson cancer center houston

Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor XL147 (SAR245408) in Combination with Paclitaxel and Carboplatin at the AACR-NCI-EORTC Conference

Exelixis, Inc. (Nasdaq:EXEL) today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with paclitaxel and carboplatin in patients with advan......